Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2-iNK cells
- Development stage
- Preclinical
- Lead developer
- Seoul National University Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral
01
Overview
GD2-iNK cells are Chimeric Antigen Receptor (CAR)-engineered natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs). They are being developed as an off-the-shelf immunotherapeutic strategy for malignant brain tumors, specifically glioblastoma (GBM). These cells are designed to target GD2-positive tumor cells, exhibiting potent, antigen-specific cytotoxicity and a favorable safety profile in preclinical models.
- Other names
- GD2-specific CAR-engineered iPSC-derived NK cellsGD-2-specific CAR-engineered iPSC-derived NK cellsGD 2-specific CAR-engineered iPSC-derived NK cells
02
Targets
GD2
Beyond the preview
Go deeper on GD2-iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2-iNK cells.